ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2012
[Access to healthcare services for elderly patients with neovascular age-related macular degeneration].
Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- [Reasons for delayed and discontinued therapy in age-related macular degeneration].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018Article
- Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration.International journal of ophthalmology · 2018Article
- Responding to a rebuttal letter concerning the BERVOLT study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.The British journal of ophthalmology · 2015Observational
- [Health services for patients with neovascular age-related macular degeneration in Germany].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2014Article
- Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.The British journal of ophthalmology · 2013Article
- [Ophthalmological aspects of the Gutenberg Health Study (GHS): an interdisciplinary prospective population-based cohort study].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeovascular (nv) age-related macular degeneration (AMD) is the leading cause of blindness in Germany and is usually treated with monthly injections of anti-VEGF agents. The current level and the estimated need of service provision for nv-AMD were assessed.
methodsCurrent levels of service provision with ranibizumab (Lucentis) were documented in 3,633 patients in the WAVE study, the currently largest observational study in Germany on the use of anti-VEGF agents. The expected need was calculated using German population figures for 2010 and available prevalence data. Both were stratified by age and gender and descriptively analyzed.
resultsA larger number of younger patients with nv-AMD (< 75 years) than expected were treated in the WAVE study. Expected need in the age groups 75-84 years and 84 years and older was much higher than the proportion of patients actually treated in these age groups (up to 3 times). Based on expected need, women accessed treatment less often than men.
conclusionIn the WAVE study, less elderly persons and in particular elderly women seemed to access treatment for nv-AMD than expected. Future studies should investigate barriers in accessing treatment for nv-AMD and how to address these problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.